Nasopharyngeal Carcinoma
📧 Sign up to get email alerts when something new happens for Nasopharyngeal Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC. [Phase 3]
A Phase 3 clinical trial from Sun Yat-sen University evaluating GAPP induction followed by concurrent chemoradiotherapy for high-risk locore…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer [Phase 2]
Phase 2 trial evaluating nivolumab and ipilimumab with or without cabozantinib for recurrent or metastatic nasopharyngeal carcinoma is curre…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) [Phase 2]
Phase 2 clinical trial evaluating nivolumab in combination with chemotherapy for nasopharyngeal carcinoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer [Phase 2]
Phase 2 trial evaluating cemiplimab plus CDX-1140 given before surgery to determine if the combination improves outcomes versus cemiplimab a…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers [Phase 1, Phase 2]
A Phase Ib/II clinical trial evaluating HMBD-001, an anti-HER3 antibody, in combination with cetuximab with or without docetaxel for advance…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma [Phase 2]
Phase 2 clinical trial investigating maintenance therapy with tislelizumab and metronomic capecitabine in high-risk locoregionally-advanced …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma [Phase 3]
Phase 3 trial evaluating Becotatug Vedotin (MRG003) in combination with a PD-1 blocker and chemoradiotherapy for high-risk locoregionally ad…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer [Phase 2]
A Phase 2 clinical trial is evaluating adding relatlimab to standard immunotherapy for recurrent or metastatic nasopharyngeal carcinoma, and…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy [Phase 2]
A Phase 2 clinical trial evaluating Becotatug Vedotin for locally advanced nasopharyngeal carcinoma with suboptimal response to induction ch…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma. [Phase 3]
Phase 3 clinical trial comparing reduced-dose versus standard-dose irradiation for low-risk clinical target volume in nasopharyngeal carcino…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA [Phase 2, Phase 3]
Clinical trial update on a phase 2/3 study using EBV DNA-guided, individualized treatment for stage II-IVB nasopharyngeal carcinoma; the tri…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma [EARLY_Phase 1]
An early-phase clinical trial evaluating Epstein-Barr virus-targeted CAR-T/TCR-T cell therapy for nasopharyngeal carcinoma, currently recrui…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: LDRT and Chemoimmunotherapy in NPC With Liver Metastasis [Phase 2]
Phase 2 clinical trial evaluating low-dose radiotherapy in combination with chemoimmunotherapy for nasopharyngeal carcinoma with liver metas…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial is planned to evaluate the use of allogeneic natural killer (NK) cells in high-risk advanced stage III-IV n…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. [Phase 1, Phase 2]
A Phase 1/2 trial is evaluating chidamide in combination with toripalimab and anlotinib for recurrent/metastatic nasopharyngeal carcinoma; t…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma [Phase 2]
Phase 2 clinical trial evaluating toripalimab in combination with platinum-based induction chemotherapy regimens for locally advanced nasoph…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC [Phase 3]
Phase 3 clinical trial evaluating the combination of Becotatug Vedotin and Sintilimab for locoregionally advanced nasopharyngeal carcinoma i…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors [Phase 2]
A Phase 2 trial investigates the combination of atezolizumab and bevacizumab in several rare solid tumors, with the study currently not recr…
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: Proton Therapy for Recurrent Nasopharyngeal Carcinoma [NA]
This clinical trial update describes a study evaluating proton therapy for recurrent nasopharyngeal carcinoma, which is currently recruiting…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response [Phase 3]
A Phase 3 trial is evaluating a reduced-dose radiotherapy approach for stage III nasopharyngeal carcinoma, and recruitment is ongoing.
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma [Phase 3]
A Phase 3 trial compares Sapylin (OK-432) inhalation to dexamethasone inhalation for CCRT-induced oral mucositis in nasopharyngeal carcinoma…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Nasopharyngeal Carcinoma Post IMRT
A ClinicalTrials.gov entry notes an active but not recruiting trial investigating Nasopharyngeal Carcinoma after IMRT, sponsored by Universi…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Response to Induction Chemotherapy
Clinical trial update on CROSSROAD comparing re-induction chemotherapy versus direct radiotherapy for locally advanced nasopharyngeal carcin…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors [Phase 1]
Phase 1 trial update of P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy, being studied in advanced or metastatic solid tumors. The study is …
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma [Phase 2]
Phase 2 trial update for MRG003 in recurrent or metastatic nasopharyngeal carcinoma. The study is currently active but not recruiting.